Patent classifications
C07C215/12
BIODEGRADABLE UV ABSORBERS
The present relates to compounds of formula (I) as defined herein. The compounds are suitable for protection against ultraviolet (UV) radiation. Further, the present invention is concerned with compositions comprising at least one compound of formula (I).
BIODEGRADABLE UV ABSORBERS
The present relates to compounds of formula (I) as defined herein. The compounds are suitable for protection against ultraviolet (UV) radiation. Further, the present invention is concerned with compositions comprising at least one compound of formula (I).
Methods of reducing color in alkanolamine compositions and compositions produced thereby
A method of reducing color in an alkanolamine is described. The method includes contacting the alkanolamine with a color-reducing amount of a borane complex effective to provide a color-reduced alkanolamine composition having a Platinum-Cobalt Color Value, according to Test Method ASTM D1209, of less than 50.
Methods of reducing color in alkanolamine compositions and compositions produced thereby
A method of reducing color in an alkanolamine is described. The method includes contacting the alkanolamine with a color-reducing amount of a borane complex effective to provide a color-reduced alkanolamine composition having a Platinum-Cobalt Color Value, according to Test Method ASTM D1209, of less than 50.
Immunomodulator compounds
Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): ##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, R.sup.4, R.sup.6a, R.sup.6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Immunomodulator compounds
Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II): ##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, R.sup.4, R.sup.6a, R.sup.6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Synthesis and application of alcohol amine with expended main carbon chain
Synthesis and application of an alcohol amine with an extended main carbon chain are provided, belonging to the field of chemical building materials. Under the action of a catalyst, tertiary amine is subjected to a two-step substitution reaction, a hydrolytic reaction and a reducing reaction to obtain a novel alcohol amine (NAA). The novel alcohol amine as provided may have a better grinding aid effect than triethanolamine while is added into cement as a cement grinding aid, and thus has a wide application prospect.
Synthesis and application of alcohol amine with expended main carbon chain
Synthesis and application of an alcohol amine with an extended main carbon chain are provided, belonging to the field of chemical building materials. Under the action of a catalyst, tertiary amine is subjected to a two-step substitution reaction, a hydrolytic reaction and a reducing reaction to obtain a novel alcohol amine (NAA). The novel alcohol amine as provided may have a better grinding aid effect than triethanolamine while is added into cement as a cement grinding aid, and thus has a wide application prospect.
CONVERSION OF GLYCOLALDEHYDE WITH AN AMINATING AGENT
A process for the conversion of glycolaldehyde with an aminating agent in the presence of hydrogen and of a catalyst in a glycolaldehyde conversion reactor, wherein one or more organic carboxylic acids are fed into the glycolaldehyde conversion reactor.
CONVERSION OF GLYCOLALDEHYDE WITH AN AMINATING AGENT
A process for the conversion of glycolaldehyde with an aminating agent in the presence of hydrogen and of a catalyst in a glycolaldehyde conversion reactor, wherein one or more organic carboxylic acids are fed into the glycolaldehyde conversion reactor.